#United States #New York #Parkinson's Disease #Medtronic #Michael J. Fox Foundation

Empowering Parkinson's Patients Through Education

In a groundbreaking partnership, the Michael J. Fox Foundation for Parkinson's Research (MJFF) and Medtronic have launched an initiative aimed at providing valuable information about deep brain stimulation (DBS) to those living with Parkinson's disease (PD) and their caregivers. This educational effort comes at a critical time as the number of individuals diagnosed with PD is expected to double by 2040, reaching an alarming total of 6 million worldwide. The goal of this collaboration is to bridge the knowledge gap surrounding DBS therapy, a treatment that has been in practice for nearly thirty years yet remains underutilized due to a lack of understanding.

Understanding Deep Brain Stimulation (DBS)

Deep brain stimulation involves the implantation of a device that sends electrical impulses to specific regions of the brain, which helps control symptoms associated with Parkinson’s disease such as tremors and rigidity. This treatment option operates in conjunction with medication and can significantly reduce the amount of medication some patients need. However, it is not suitable for everyone, making education about its potential benefits and risks paramount.

Sohini Chowdhury, Chief Program Officer at MJFF, emphasized the foundation’s mission to facilitate informed decision-making. "Our urgent mission is to accelerate a cure for Parkinson's by advancing the most promising research. Partnerships with industry help us do more for people and families by expanding access to clear, practical resources that support informed decisions and meaningful participation in our mission."

Comprehensive Educational Resources

To support this mission, MJFF and Medtronic are creating a wealth of educational materials designed to demystify DBS. These resources include:

• - A dedicated online resource hub, “The Live On with DBS Education Hub,” which offers up-to-date information on the therapy and its implications.
• - A practical guide detailing what individuals should expect when considering DBS treatments.
• - Interactive webinars to engage patients and families in discussions about DBS.
• - A comprehensive overview of the latest research related to Parkinson’s and DBS.

The collaboration with Medtronic, which has over 30 years of experience in DBS therapy and has helped more than 200,000 individuals globally, enhances MJFF's ability to inform the Parkinson's community effectively.

“As innovators, we have a responsibility to ensure that people not only have access to these life-changing technologies but are also equipped with the necessary knowledge to understand their options,” stated Andrea Swain, President of Neuromodulation at Medtronic.

Real Stories from Patients

A testimonial from John L. Lipp, a Parkinson's patient and participant in the Adaptive DBS Algorithm for Personalized Therapy in Parkinson Disease (ADAPT-PD) clinical trial, illustrates the profound impact of DBS on personal experiences. "Living with Parkinson's has reminded me that no two days are alike. My experience with DBS the past five years has been meaningful; it's helped me stay connected to things I love, like being active with my family and friends."

His remarks underline the importance of making informed choices about treatment options and the need for comprehensive support.

The Foundation’s Ongoing Commitment

Since its establishment in the year 2000, MJFF has dedicated over $29 million to research specifically investigating DBS for Parkinson's, with a focus on improving technology and treatment experiences. Furthermore, they manage the Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD), ensuring the collection of data that aids in refining care decisions and enhancing patient outcomes.

As the partnership continues to roll out educational materials, both MJFF and Medtronic reinforce their commitment to fostering informed discussions within the Parkinson’s community. With the increasing prevalence of PD, such initiatives are essential for promoting awareness and understanding around effective treatment options.

For more information, visit michaeljfox.org/dbs, your gateway to exploring the resources available through this vital educational hub.